Can I read Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis on EtoBox?

Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis by Katie A. Parsels; Robert W. Seabury; Stephanie Zyck; Christopher D. Miller; Satish Krishnamurthy; William Darko; Luke A. Probst; Julius Gene Latorre; Gregory M. Cwikla; Elizabeth A. Feldman is a Medicine article available to read on EtoBox.

What is Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis about?

## Background: There is limited information directly comparing andexanet alfa (aa) versus four-factor prothrombin complex concentrate (4f-pcc) in intracranial hemorrhage (ich) on apixaban or rivaroxaban. ## Objective: The objective of this study was to compare the effectiveness and safety of aa versus 4f-pcc in ich on apixaban or rivaroxaban. ## Methods: This retrospective, matched, cohort analysis was conducted at a single healthcare system. patients were matched based on baseline ich volume. the primary outcome was good or excellent ich hemostasis, which was defined as a 35% or less increase in ich volume within 24 h following aa or 4f-pcc administration. the secondary outcome was thrombotic events within 14 days following aa or 4f-pcc administration. ## Results: In total, 26 aa and 26 4f-pcc patients were included in this matched cohort analysis. both groups had comparable rates of good or excellent ich hemostasis (aa: 92.3% vs. 4f-pcc: 88.5%, p = 1.000). thrombotic events within 14-days were not significantly different (aa: 26.9% vs. 4f-pcc: 11.5%, p = 0.159). ## Conclusion and relevance: This study found no significant differences in good or excellent ich hemostasis within 24-

Who reads Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis?

Author

Katie A. Parsels; Robert W. Seabury; Stephanie Zyck; Christopher D. Miller; Satish Krishnamurthy; William Darko; Luke A. Probst; Julius Gene Latorre; Gregory M. Cwikla; Elizabeth A. Feldman

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)